feldmanEva Feldman, M.D., Ph.D.

Russell N. DeJong professor of Neurology

Director of the Taubman Institute

Director of the Program for Research & Discovery

New Hope in the Battle against ALS

Amyotrophic Lateral Sclerosis (ALS) — also known as Lou Gehrig’s disease — is a neurodegenerative disorder that causes nerve cells to weaken and die. Some 30,000 Americans currently have the disease, which progressively destroys the neurons that control voluntary muscles, leaving affected people unable to move, speak and eventually breathe. It is almost invariably fatal, and until now, there has been no effective treatment.

Eva Feldman has been studying ALS her entire medical career, and after years of painstaking laboratory study, has developed the first stem cell treatment for the disease. With the support of Taubman Institute funding, she is currently leading a human clinical trial to test this new therapeutic approach, which represents the first time that stem cells have been injected into the human spinal cord. The trial is now in Phase 2, and so far 28 patients have undergone this revolutionary therapy, with no serious side effects.

At the same time, her team of scientists is working to improve the ability of the stem cells to deliver life-preserving proteins to the nerve cells under attack in ALS. They are also adapting this stem cell model to the treatment of Alzheimer’s disease, which afflictes more than 5 million people in America alone.
Besides being the director of the Taubman Institute, Feldman also directs the U-M Program for Neurology Research Discovery, whose 30 scientists study a wide variety of nerve diseases, including muscular dystrophy and spinal cord injury. She is one of the world’s authorities on diabetic neuropathy. Last year she discovered a previously unknown link between triglycerides, a common fat in the blood, and the progression of nerve damage in patients. Her laboratory is working to understand the mechanism behind this connection and ways to help preserve nerve function through therapeutic intervention.

Research Findings:


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift


Follow Us / Friend Us

Discovery-driven research that matters


Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding


The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more

Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  


Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster


video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists